At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 287 enrolled
Drug / intervention
vildagliptin +1 moredrug
Likely dose
vildagliptin 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Active-controlled Study to Compare the Effect of 16 Weeks Treatment With Vildagliptin to Pioglitazone as add-on Therapy to Metformin in Type 2 Diabetic Patients Inadequately Controlled With Metformin Monotherapy
In Brief
A Phase 4 clinical trial evaluating vildagliptin and Pioglitazone for Type 2 Diabetes. Completed, enrolled 287 participants across 15 sites.
Detailed Summary
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2009
Primary CompletionMar 2013
First PostedJun 2013
TodayJul 2026
First PostedJun 21, 2013
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.0 years ago
Interventions
vildagliptindrug
vildagliptin 50mg bid for 16 weeks
Pioglitazonedrug
Pioglitazone 15mg bid for 16 weeks